Your session is about to expire
← Back to Search
Viltolarsen for Duchenne Muscular Dystrophy
Study Summary
This trial is testing a new drug for Duchenne Muscular Dystrophy. The drug is given intravenously once a week for 48 weeks. The trial is open to patients who are 8 years or older, and who can walk or not walk.
- Duchenne Muscular Dystrophy
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What assessments have been made to determine the safety of Viltolarsen for human consumption?
"The safety profile of Viltolarsen was scored a 2. This is because despite some evidence supporting its security, no data has yet been found to prove the drug's effectiveness at this time."
Is this a groundbreaking research endeavor?
"Currently, 4 ongoing clinical trials with Viltolarsen are occuring in 8 cities and 20 countries. The first trial involving this drug was conducted by NS Pharma, Inc. back in 2020; it had 74 participants and finished its Phase 3 process of medication approval. Since then, three further investigations have concluded their course."
Is there presently an enrollment process for this clinical experiment?
"Clinicaltrials.gov confirms that this medical trial is presently not enrolling any patients, as the last update was made on June 30th 2022. Despite this, there are 90 other research projects actively seeking volunteers at present."
How many participants are currently engaged in this clinical trial?
"Unfortunately, this research trial is no longer open to new participants. It was posted on the 1st of July 2021 and concluded at the end of June 2022. However, there are still 86 trials recruiting individuals with becker muscular dystrophy and 4 studies for Viltolarsen actively interviewing potential volunteers."
Has Viltolarsen been tested in prior laboratory experiments?
"Currently, four clinical trials are exploring Viltolarsen with two of the studies in Phase 3. While largely held in Rome, Oregon, there is a total of 70 trial sites across the world looking into potential applications for this treatment."
Who else is applying?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger